- •In high-risk breast cancer, longer time from surgery to endocrine therapy was associated with worse recurrence-free survival.
- •High-risk patients may benefit from early systemic endocrine therapy, and delays may have negative oncologic consequences.
- •Delaying endocrine therapy in patients receiving radiotherapy should be carefully considered, weighing patient risk factors
In hormone receptor-positive breast cancer (HRPBC), endocrine therapy is often initiated after adjuvant radiotherapy given concerns of radiation fibrosis. No studies have investigated how this may impact outcomes in high-risk patients undergoing neoadjuvant chemotherapy (NAC).
Females with nonmetastatic HRPBC receiving NAC from 2011 to 2017 were identified from our multi-institutional database. Interval from surgery to endocrine therapy (ISET) was calculated in weeks. Recurrence-free survival (RFS) and overall survival (OS) were evaluated with Kaplan-Meier and Cox proportional hazards modeling.
Of 280 patients, 179 (64%) received adjuvant radiotherapy; all deaths (n = 25) and 90% (n = 27) of recurrences occurred in this group, which was the focus of subsequent analysis.
Median follow-up was 49 months. Recurrences were predominantly distant metastases (n = 21, 81%). Median ISET was 12 weeks (range 0–55 weeks). On multivariable analysis, ISET >14 weeks was independently associated with worse RFS (HR 3.20, 95% C.I. 1.22–8.40, P = 0.02) but not OS (HR 2.15, 95% C.I. 0.75–6.15, P = 0.15).
In patients with HRPBC treated with NAC and adjuvant radiation, increasing ISET is associated with adverse oncologic outcomes.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to The American Journal of Surgery
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: Asco clinical practice guideline focused update.J Clin Oncol. 2019 Feb 10; 37: 423-438
- Adjuvant endocrine therapy for women with hormone receptor–positive breast cancer: Asco clinical practice guideline focused update.J Clin Oncol. 2019; 37: 423-438
- Changes in radiation sensitivity and steroid receptor content induced by hormonal Agents and ionizing radiation in breast cancer cells in vitro.Acta Oncol. 1996; 35: 1011-1019
- Modulation in the radiosensitivity of Mcf-7 human breast carcinoma cells by 17b-estradiol and tamoxifen.Br J Radiol. 1989 Dec; 62: 1079-1083
- Radiosensitivity of human breast cancer cell lines of different hormonal responsiveness. Modulatory effects of oestradiol.Int J Radiat Biol. 1996 Aug; 70: 161-169
- Letrozole sensitizes breast cancer cells to ionizing radiation.Breast Cancer Res. 2005; 7: R156-R163
- Optimal combination of radiotherapy and endocrine drugs in breast cancer treatment.Cancer Radiother. 2013 Jun; 17: 208-214
- Sequencing of tamoxifen and radiotherapy after breast-conserving surgery in early-stage breast cancer.J Clin Oncol. 2005 Jan 1; 23: 24-29
- Impact of concurrent versus sequential tamoxifen with radiation therapy in early-stage breast cancer patients undergoing breast conservation treatment.J Clin Oncol. 2005 Jan 1; 23: 11-16
- Retrospective analysis of concurrent vs. Sequential Administration of radiotherapy and hormone therapy using Aromatase inhibitor for hormone receptor-positive postmenopausal breast cancer.Anticancer Res. 2009 Nov; 29: 4791-4794
- Treatment sequence of Aromatase inhibitors and radiotherapy and long-term outcomes of breast cancer patients.Anticancer Res. 2014 Aug; 34: 4311-4314
- Influence of concurrent anastrozole on Acute and late side effects of whole breast radiotherapy.Am J Clin Oncol. 2011 Jun; 34: 245-248
- Sequence of radiotherapy with tamoxifen in conservatively Managed breast cancer does not affect local relapse rates.J Clin Oncol. 2005 Jan 1; 23: 17-23
- Radiotherapy-related lung fibrosis enhanced by tamoxifen.J Natl Cancer Inst. 1996 Jul 3; 88: 918-922
- Effects of tamoxifen on pulmonary fibrosis after cobalt-60 radiotherapy in breast cancer patients.Radiother Oncol. 2002 Aug; 64: 171-175
- Role of systemic therapy in the development of lung sequelae after conformal radiotherapy in breast cancer patients.Int J Radiat Oncol Biol Phys. 2011 Jul 15; 80: 1109-1116
- The effects of tamoxifen on radiation-induced pulmonary fibrosis in Wistar Albino rats: results of an experimental study.Breast. 2006 Jun; 15: 456-460
- Comparison of the effects of Aromatase inhibitors and tamoxifen on radiation-induced lung toxicity: results of an experimental study.Support Care Cancer. 2013 Mar; 21: 811-817
- Concurrent versus sequential radiotherapy and tamoxifen in breast cancer - the conset trial is launched.Acta Oncol. 2011 Jan; 50: 154-155
- Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy.J Clin Oncol. 2007 Oct 1; 25: 4414-4422
- Toxicity criteria of the radiation therapy oncology group (Rtog) and the European organization for research and treatment of cancer (Eortc).Int J Radiat Oncol Biol Phys. 1995 Mar 30; 31: 1341-1346
Published online: February 24, 2023
Accepted: February 23, 2023
Received in revised form: January 12, 2023
Received: November 5, 2022
Publication stageIn Press Journal Pre-Proof
© 2023 Elsevier Inc. All rights reserved.